Obesity, incretin-based therapies, and cardiovascular disease in women
Miro Salih, Yannicke A. J. Sloots, Martin E. W. Hemels, Laura M. G. Meems, Maarten J. G. Leening, Chahinda Ghossein-Doha · 2026
Read Obesity, incretin-based therapies, and cardiovascular disease in women by Miro Salih, Yannicke A. J. Sloots, Martin E. W. Hemels, Laura M. G. Meems, Maarten J. G. Leening, Chahinda Ghossein-Doha (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13615230.txt.
Description
Miro Salih and co-authors review obesity and heart disease in women in this 2026 survey. Female weight gain follows hormone turns from first periods to menopause, plus pregnancy-linked risks that echo for decades. New incretin-based drugs add strong weight loss and heart benefits to the toolkit.
Yet how those drugs work in women specifically, and for how long, is under-studied. Fertility concerns and care access gaps also fall harder on women. Heart failure with stiff pumping and chest pain without blocked arteries hit obese women more often. The authors urge a life-course, sex-aware approach to treatment.
Catalog record
| CREATOR | Miro Salih, Yannicke A. J. Sloots, Martin E. W. Hemels, Laura M. G. Meems, Maarten J. G. Leening, Chahinda Ghossein-Doha |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |